vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Newsmax Inc. (NMAX). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $52.2M, roughly 1.6× Newsmax Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -5.7%, a 28.5% gap on every dollar of revenue. 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $1.8M).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Newsmax Inc. is a U.S.-headquartered media and broadcasting company that offers news coverage, political commentary, opinion pieces, and lifestyle programming across cable TV, official websites, mobile apps, and streaming platforms. It mainly caters to U.S. domestic audiences, with a core focus on conservative-oriented current affairs content segments.
FDMT vs NMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $52.2M |
| Net Profit | $19.4M | $-3.0M |
| Gross Margin | — | 36.7% |
| Operating Margin | 17.3% | -9.0% |
| Net Margin | 22.8% | -5.7% |
| Revenue YoY | 8508900.0% | — |
| Net Profit YoY | 139.1% | — |
| EPS (diluted) | $0.43 | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $52.2M | ||
| Q3 25 | $90.0K | $45.3M | ||
| Q2 25 | $15.0K | $46.4M | ||
| Q1 25 | $14.0K | $45.3M | ||
| Q4 24 | $1.0K | — | ||
| Q3 24 | $3.0K | — | ||
| Q2 24 | $5.0K | — | ||
| Q1 24 | $28.0K | — |
| Q4 25 | $19.4M | $-3.0M | ||
| Q3 25 | $-56.9M | $-4.1M | ||
| Q2 25 | $-54.7M | $-75.2M | ||
| Q1 25 | $-48.0M | $-17.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-43.8M | — | ||
| Q2 24 | $-35.0M | — | ||
| Q1 24 | $-32.4M | — |
| Q4 25 | — | 36.7% | ||
| Q3 25 | — | 35.3% | ||
| Q2 25 | — | 38.0% | ||
| Q1 25 | — | 47.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 17.3% | -9.0% | ||
| Q3 25 | -67983.3% | -15.9% | ||
| Q2 25 | -396373.3% | -164.5% | ||
| Q1 25 | -383007.1% | -25.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1704400.0% | — | ||
| Q2 24 | -849120.0% | — | ||
| Q1 24 | -136200.0% | — |
| Q4 25 | 22.8% | -5.7% | ||
| Q3 25 | -63195.6% | -9.1% | ||
| Q2 25 | -364386.7% | -161.9% | ||
| Q1 25 | -342657.1% | -38.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1461433.3% | — | ||
| Q2 24 | -699060.0% | — | ||
| Q1 24 | -115717.9% | — |
| Q4 25 | $0.43 | $0.15 | ||
| Q3 25 | $-1.01 | $-0.03 | ||
| Q2 25 | $-0.98 | $-0.59 | ||
| Q1 25 | $-0.86 | $-0.49 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.79 | — | ||
| Q2 24 | $-0.63 | — | ||
| Q1 24 | $-0.66 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $106.0M |
| Total Assets | $566.7M | $239.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $20.4M | ||
| Q3 25 | $305.1M | $14.2M | ||
| Q2 25 | $293.2M | $33.8M | ||
| Q1 25 | $321.4M | $126.7M | ||
| Q4 24 | $424.9M | — | ||
| Q3 24 | $501.9M | — | ||
| Q2 24 | $541.9M | — | ||
| Q1 24 | $525.9M | — |
| Q4 25 | $505.7M | $106.0M | ||
| Q3 25 | $369.0M | $106.0M | ||
| Q2 25 | $420.9M | $106.9M | ||
| Q1 25 | $469.7M | $177.4M | ||
| Q4 24 | $510.6M | — | ||
| Q3 24 | $552.9M | — | ||
| Q2 24 | $588.3M | — | ||
| Q1 24 | $600.6M | — |
| Q4 25 | $566.7M | $239.8M | ||
| Q3 25 | $424.0M | $233.3M | ||
| Q2 25 | $473.6M | $259.8M | ||
| Q1 25 | $515.7M | $278.2M | ||
| Q4 24 | $560.4M | — | ||
| Q3 24 | $604.0M | — | ||
| Q2 24 | $620.1M | — | ||
| Q1 24 | $629.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $2.6M |
| Free Cash FlowOCF − Capex | $28.5M | $1.8M |
| FCF MarginFCF / Revenue | 33.5% | 3.4% |
| Capex IntensityCapex / Revenue | 0.1% | 1.7% |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $-107.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $2.6M | ||
| Q3 25 | $-46.5M | $-68.1M | ||
| Q2 25 | $-43.4M | $-23.2M | ||
| Q1 25 | $-47.8M | $-15.7M | ||
| Q4 24 | $-134.6M | — | ||
| Q3 24 | $-29.4M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-29.1M | — |
| Q4 25 | $28.5M | $1.8M | ||
| Q3 25 | $-46.6M | $-69.2M | ||
| Q2 25 | $-43.4M | $-23.8M | ||
| Q1 25 | $-48.4M | $-15.8M | ||
| Q4 24 | $-138.4M | — | ||
| Q3 24 | $-31.2M | — | ||
| Q2 24 | $-30.6M | — | ||
| Q1 24 | $-29.8M | — |
| Q4 25 | 33.5% | 3.4% | ||
| Q3 25 | -51765.6% | -152.9% | ||
| Q2 25 | -289620.0% | -51.3% | ||
| Q1 25 | -345635.7% | -34.9% | ||
| Q4 24 | -13837100.0% | — | ||
| Q3 24 | -1038966.7% | — | ||
| Q2 24 | -611840.0% | — | ||
| Q1 24 | -106421.4% | — |
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 101.1% | 2.4% | ||
| Q2 25 | 440.0% | 1.3% | ||
| Q1 25 | 4507.1% | 0.2% | ||
| Q4 24 | 378600.0% | — | ||
| Q3 24 | 59266.7% | — | ||
| Q2 24 | 6980.0% | — | ||
| Q1 24 | 2535.7% | — |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
NMAX
| Advertising | $33.9M | 65% |
| Affiliate Fee | $8.3M | 16% |
| Subscription And Circulation | $6.2M | 12% |
| Products | $2.6M | 5% |
| Supplement Sales | $1.1M | 2% |
